ArticleNanotechnology, science and applications2025
Rapid Replenishment of Phylloquinone in the Plasma and Liver Using Hyaluronan-Based Nanocapsules Reverses Endothelial Dysfunction in Mice.
Article in Nanotechnology, science and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As vitamin K Methods: PK pharmacokinetics in plasma, liver and aorta were analysed after single, oral administration of PK (10 mg/kg) in oil (PK-Oil) or encapsulated in hyaluronan-based nanocapsules with oil core (PK-Oil-HyC12) in mice using liquid chromatography-tandem mass spectrometry with atmospheric pressure chemical ionization method. PK-Oil-HyC12 absorption and nanocapsules distribution in lymphatic system was determined using a cycloheximide-based chylomicron flow blockage and intravital confocal microscopy. The endothelial function was analyzed in vivo by MRI in mice with dietary PK deficiency after 7-day supplementation with PK-Oil or PK-Oil-HyC12 (0.5 mg PK/kg). Results: After a single, oral dose of PK-Oil-HyC12 in mice total exposure of PK (AUC values) was 2-4 times higher as compared to PK-Oil in plasma and liver, with no difference in PK content in the aorta. The efficient absorption and distribution of nanocapsules occurred mainly via a chylomicron-independent lymphatic route. Importantly, 7-day PK-Oil-HyC12 supplementation restored impaired endothelium-dependent vasodilation in the aorta of PK-deficient mice, while PK-Oil was ineffective. Conclusion: The improved bioavailability of PK, when administered in the form of hyaluronan-based nanocapsules, afforded the rapid replenishment of systemic PK and the reversal of endothelial dysfunction induced by low PK levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.